

**Table 18. Characteristics of Fusion Inhibitors**

Generic Name/ Trade Name	Form	Dosing Recommendations	Bio- availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Enfuvirtide/</b> Fuzeon™	<ul style="list-style-type: none"> <li>• Injectable – in lyophilized powder</li> <li>• Each single-use vial contains 108 mg of enfuvirtide to be reconstituted with 1.1 mL of Sterile Water for injection for delivery of approximately 90 mg/1 mL</li> </ul>	90 mg (1 mL) subcutaneously (SC) two times/day	84.3% (SC compared to IV)	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	<p>Store at room temperature</p> <p>Reconstituted solution should be stored under refrigeration at 2°C to 8°C (36°F to 46°F) and used within 24 hours</p>	<ul style="list-style-type: none"> <li>• Local injection site reactions (pain, erythema, induration, nodules and cysts, pruritus, ecchymosis)</li> <li>• Increased rate of bacterial pneumonia</li> <li>• Hypersensitivity reaction (&lt;1%) - symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases; may recur on rechallenge</li> </ul>